OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:03 UTC. Every row links to its source record.

SOST sclerostin

ENSG00000167941 · protein coding · Open Targets profile

Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. .

1 of the 4 drugs recorded against SOST is approved, and 1 more reached Phase 3

Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.

1 antibody drug at Approved: ROMOSOZUMAB1 antibody drug at Phase 3: SETRUSUMAB1 antibody drug at Phase 2: BLOSOZUMAB1 unknown drug at Phase 1: AMG-167Antibody 3Unknown 1Approved 1Phase 3 1Phase 2 1Phase 1 1

Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.

In 1 of 15 cancers, the evidence for SOST comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751breast cancerbreast cancerbreast carcinomabreast carcinomaosteosarcomaosteosarcomaoral cavity squamous cell carcinomaoral cavity squamous cell carcinomaFamilial prostate cancerFamilial prostate cancerprostate carcinomaprostate carcinomaprostate cancerprostate cancerplasma cell myelomaplasma cell myelomarenal cell carcinomarenal cell carcinomaretinoblastomaretinoblastomaovarian neoplasmovarian neoplasmovarian neoplasm: germline 0.10diaphyseal medullary stenosis-bone mali…diaphyseal medullary stenosis-bone malignancy syndromeGorham-Stout diseaseGorham-Stout diseaseclear cell renal carcinomaclear cell renal carcinomahyperparathyroidism 4hyperparathyroidism 4

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Ligand
Antibody
Approved Drug, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
PROTAC
Small Molecule Binder

gnomAD loss of function constraint: o/e 0.8359400033950806 (upper bound 1.3068000078201294). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

Principal investigators and study chairs on 36 registry trials, updated in the last three years, of the most advanced drugs against SOST (romosozumab, setrusumab, blosozumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.

14 of 35 trials of drugs against SOST have sites only in United States

Registry trials of romosozumab, setrusumab, blosozumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 27 of 35 have all sites in one country.

Sites only in this groupSites here and elsewhere
United StatesUnited States: 14 trials with sites only hereUnited States: 8 trials with sites here and elsewhere22ChinaChina: 4 trials with sites only hereChina: 1 trials with sites here and elsewhere5EuropeEurope: 3 trials with sites only hereEurope: 8 trials with sites here and elsewhere11JapanJapan: 1 trials with sites only hereJapan: 3 trials with sites here and elsewhere4OtherOther: 5 trials with sites only hereOther: 6 trials with sites here and elsewhere11

Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.

5 trials of drugs against SOST were stopped early; 1 give no reason

Terminated, withdrawn and suspended interventional trials of romosozumab, setrusumab, blosozumab, AMG-167, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 5 most recent of 5.

  • Ph2NCT06973109briefwhy it stopped
    withdrawn · 2026-06-04 · University of Pittsburgh · Romosozumab, Placebo Romosozumab
    “Investigator left the institution”
  • Ph2NCT05312697briefwhy it stopped
    terminated · 2025-07-23 · Ultragenyx Pharmaceutical Inc · Setrusumab
    “Sponsor decision not related to safety concerns”
  • Ph2NCT03216486briefwhy it stopped
    withdrawn · 2023-07-03 · Ultragenyx Pharmaceutical Inc · matched by the registry's drug synonyms
    “Administrative Reason”
  • Ph2NCT01806610briefwhy it stopped
    withdrawn · 2022-09-14 · Ultragenyx Pharmaceutical Inc · matched by the registry's drug synonyms
    No reason given
  • Ph1NCT02337387briefwhy it stopped
    terminated · 2019-01-22 · Eli Lilly and Company · Blosozumab
    “Protocol stopping criteria (safety) were met.”
Paediatric incentives and obligations for SOST's drugs

For romosozumab, setrusumab, blosozumab, AMG-167: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.

  • FDA pediatric target list: no · SOST is not on the list
    Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
  • EU paediatric investigation plan: yes · EMEA-001075-PIP04-15-M07 (romosozumab, Treatment of osteoporosis): PM: decision on the application for modification of an agreed PIP, 24 Oct 2024; EMEA-002169-PIP01-17-M03 (setrusumab, Treatment of osteogenesis imperfecta): PM: decision on the application for modification of an agreed PIP, 5 Jul 2024
    Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
  • EU orphan designation: no · No EU orphan designation names romosozumab, setrusumab, blosozumab, amg-167
    Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
  • Authorised in the EU: yes · Evenity: authorised since 9 Dec 2019
    Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Evenity, 2026-11-11
  • FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link
    Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
  • FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of romosozumab, setrusumab, blosozumab, amg-167
    Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
  • Registered studies open to children: yes · 7 interventional studies of romosozumab, setrusumab, blosozumab, amg-167 include patients under 18; 6 are recruiting, not yet recruiting or active
    Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12

Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

All 4 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
ROMOSOZUMABAntibodyphase 4osteoporosis, bone fracture, postmenopausal osteoporosis, bone disorder, spinal fracture, anorexia nervosa, osteogenesis imperfecta, hip fractureOpen Targets · ChEMBL
SETRUSUMABAntibodyphase 3osteogenesis imperfecta, hypophosphatasia, chronic kidney diseaseOpen Targets · ChEMBL
BLOSOZUMABAntibodyphase 2osteoporosisOpen Targets · ChEMBL
AMG-167Unknownphase 1osteoporosisOpen Targets · ChEMBL